Compare PMT & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMT | EVO |
|---|---|---|
| Founded | 2009 | 1993 |
| Country | United States | Germany |
| Employees | 7 | 4553 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 879.9M | 1.0B |
| IPO Year | N/A | N/A |
| Metric | PMT | EVO |
|---|---|---|
| Price | $9.66 | $1.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $13.50 | $7.00 |
| AVG Volume (30 Days) | ★ 1.7M | 45.5K |
| Earning Date | 05-05-2026 | 04-08-2026 |
| Dividend Yield | ★ 13.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | $1.55 | $10.05 |
| P/E Ratio | $12.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.56 | $1.94 |
| 52 Week High | $13.80 | $4.32 |
| Indicator | PMT | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 39.29 | 25.42 |
| Support Level | N/A | N/A |
| Resistance Level | $12.26 | $3.36 |
| Average True Range (ATR) | 0.25 | 0.09 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 9.91 | 1.51 |
PennyMac Mortgage Investment Trust is a specialty finance company that invests mainly in residential mortgage loans and mortgage-related assets. The company's operations include activities such as the production and servicing of financial securities based on residential loans and the pooling and reselling of high-credit-quality mortgages. The company operates through three segments: correspondent production, credit-sensitive strategies, interest-rate-sensitive strategies. The Credit sensitive strategies segment generates income via investments in CRT arrangements, subordinate MBS, distressed loans, and real estate.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.